Your browser doesn't support javascript.
loading
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa, Delphine; Mauro, Michael J; Boquimpani, Carla; Minami, Yosuke; Lomaia, Elza; Voloshin, Sergey; Turkina, Anna; Kim, Dong-Wook; Apperley, Jane F; Abdo, Andre; Fogliatto, Laura Maria; Kim, Dennis Dong Hwan; le Coutre, Philipp; Saussele, Susanne; Annunziata, Mario; Hughes, Timothy P; Chaudhri, Naeem; Sasaki, Koji; Chee, Lynette; García-Gutiérrez, Valentin; Cortes, Jorge E; Aimone, Paola; Allepuz, Alex; Quenet, Sara; Bédoucha, Véronique; Hochhaus, Andreas.
Afiliação
  • Réa D; DMU Hématologie, Hôpital Saint-Louis, Paris, France.
  • Mauro MJ; Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Boquimpani C; HEMORIO, State Institute of Hematology Arthur de Siquiera Cavalcanti, Rio de Janeiro, Brazil.
  • Minami Y; Oncoclínica Centro de Tratamento Oncológico, Rio de Janeiro, Brazil.
  • Lomaia E; Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Voloshin S; Institute of Oncology and Hematology, Almazov National Medical Research Centre, St Petersburg, Russia.
  • Turkina A; Hematology and Bone Marrow Transplantation, Russian Research Institute of Hematology and Transfusiology, St Petersburg, Russia.
  • Kim DW; Scientific and Advisory Department of Hemotherapy of Myeloproliferative Disorders, National Research Center for Hematology, Moscow, Russia.
  • Apperley JF; Hematologic Tumor Medicine Department, Uijeongbu Eulji Medical Center, Eulji University, Uijeongbu, South Korea.
  • Abdo A; Department of Immunology and Inflammation, Centre for Haematology Imperial College London, London, United Kingdom.
  • Fogliatto LM; Hemato-Oncology Department, Instituto do Câncer do Estado de São Paulo (ICESPSP), São Paulo, Brazil.
  • Kim DDH; Hematology and Hemotherapy Department, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.
  • le Coutre P; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
  • Saussele S; Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Annunziata M; Department of Haematology and Oncology, III. Medizinische Klinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.
  • Hughes TP; Division of Hematology, AORN Cardarelli, Naples, Italy.
  • Chaudhri N; South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, Australia.
  • Sasaki K; Hematology, Stem Cell Transplant and Cellular Therapy Section, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia.
  • Chee L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • García-Gutiérrez V; Haematology Department, Peter MacCallum Cancer Center-The Royal Melbourne Hospital, Melbourne, Australia.
  • Cortes JE; Servicio de Hematología, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain.
  • Aimone P; Georgia Cancer Center, Augusta, GA.
  • Allepuz A; Novartis Pharma AG, Basel, Switzerland; and.
  • Quenet S; Novartis Pharma AG, Basel, Switzerland; and.
  • Bédoucha V; Novartis Pharma AG, Basel, Switzerland; and.
  • Hochhaus A; Novartis Pharma AG, Basel, Switzerland; and.
Blood ; 138(21): 2031-2041, 2021 11 25.
Article em En | MEDLINE | ID: mdl-34407542
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Quinolinas / Leucemia Mieloide de Fase Crônica / Niacinamida / Inibidores de Proteínas Quinases / Compostos de Anilina / Antineoplásicos / Nitrilas Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Quinolinas / Leucemia Mieloide de Fase Crônica / Niacinamida / Inibidores de Proteínas Quinases / Compostos de Anilina / Antineoplásicos / Nitrilas Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França